PET Imaging and Olanzapine Treatment in Borderline Personality Disorder

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The overall design of the study is to perform both a PET and MRI scan on objectively identified borderline personality disorder patients, to treat them with olanzapine for 8 weeks, and to then re-scan the patients with PET.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Minnesota; University of Minnesota - Clinical and Translational Science Institute
• Collaborator: Eli Lilly and Company
• Treatments: Olanzapine

Criteria

Inclusion Criteria:

1. Age 18-45 years

2. Diagnosis: borderline personality disorder by DSM-IV criteria

3. Gender: Female

4. May have history of substance use and other Axis II disorders

Exclusion Criteria:

1. Axis I diagnosis of schizophrenia, schizoaffective disorder, or bipolar I disorder during the subject's lifetime. No current major depression or PTSD.

2. Treatment with psychotropic medication in the previous month.

3. Medical disorder that would influence outcome of the study - e.g. epilepsy, thyroid disease, HIV, etc.

4. Medical disorder that would not allow use of olanzapine

5. Active substance abuse or dependence

6. Previous adverse reaction to olanzapine

7. Females whom are pregnant or nursing